Inactivated viral vaccines for TBE prevention in endemic regions
This page catalogs 3 tick-borne encephalitis vaccine products spanning the first US-licensed TBE vaccine and established European formulations. TBE vaccination has been routine in endemic European countries for decades, with the 2021 US licensure of Ticovac representing the first FDA-approved option for American travelers to endemic regions.
Last updated: April 2026.
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Ticovac | Tick-borne encephalitis vaccine | Pfizer | Inactivated viral | FDA Licensed, 2021 | First US-licensed TBE vaccine |
| FSME-Immun | TBE vaccine | Pfizer (Baxter legacy) | Inactivated viral | EMA Authorized | European TBE; same product as Ticovac |
| Encepur | TBE vaccine | GSK (Novartis legacy) | Inactivated viral | EMA Authorized | European TBE vaccine |
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026) and EMA Medicines database. Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.